A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Patients must have measurable disease

• Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator

• ECOG PS: 0-1

Exclusion Criteria:

• Subjects with centrally located squamous cell carcinoma of the lung